Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Uterine fibroids Stories

2013-08-27 23:33:38

DailyGossip.org reviews the newest and one of the most appreciated natural treatments for fibroids, at the moment. The treatment, "Fibroids Miracle", is described as a highly effective natural cure. Denver, Colorado (PRWEB) August 26, 2013 According to the Fibroids Miracle review published by DailyGossip.org on August 26, this new treatment is effective and patients who tried it were able to overcome the disease. http://www.DailyGossip.org reveals that the new method was...

2013-08-22 23:00:46

Daily Gossip reviews one of the latest natural fibroids treatments. The Fibroids Miracle Review presents a simple, yet really efficient cure for fibroids. Denver, Colorado (PRWEB) August 22, 2013 According to the review published by http://www.DailyGossip.org on August 23, Fibroids Miracle System is an eBook released by famous medical researcher, Amanda Leto. Amanda Leto found a new natural cure for Fibroids, which makes pills and medical interventions such as surgery completely...

2013-07-25 04:21:28

LIVERMORE, Calif., July 25, 2013 /PRNewswire/ -- The Fibroid Treatment Collaborative, with centers in Chicago, IL and Austin TX, announced today the adoption of the Acessa Procedure as its primary surgical therapy for patients suffering from uterine fibroids. Traditional surgical interventions, such as hysterectomy or myomectomy, involve long recovery periods and other minimally invasive solutions may only treat symptoms, not the fibroids. "Fibroids are highly-symptomatic; causing...

2013-07-23 08:31:30

LYNBROOK, N.Y., July 23, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum; CCH) in the U.S., announces that a poster titled, "Biomechanical Evaluation of Human Uterine Fibroids after Exposure to Purified Clostridial Collagenase" was presented today at the Society for the Study of Reproduction 46(th) Annual Meeting taking...

2013-07-11 04:20:37

LIVERMORE, Calif., July 11, 2013 /PRNewswire/ -- Forest Park Medical Center Frisco, part of the Dallas-based physician-owned hospital system dedicated to providing unsurpassed surgical care, along with Halt Medical, announced that it is the first center in Texas to offer patients the Acessa(TM) Procedure, which destroys uterine fibroids in an outpatient same day surgery. "Our first patient was delighted with the speed of symptom resolution and return to normal activity," said Dr....

2013-07-10 04:20:36

LIVERMORE, Calif., July 10, 2013 /PRNewswire/ -- Halt Medical is very pleased to announce that the American Medical Association (AMA) Current Procedure Terminology (CPT) Panel has established a new CPT® code specifically for Radiofrequency (RF) Ablation of Uterine Fibroids. The new CPT code reads: 0336T Laparoscopy, surgical, ablation of uterine fibroid(s), including intraoperative ultrasound guidance...

2013-06-25 08:30:10

PARSIPPANY, N.J., June 25, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that Health Canada has approved the company's application to market FIBRISTAL(TM) (ulipristal acetate) for the treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age who are eligible for surgery. The breakthrough first-in-class oral treatment offers an important new option for women in Canada with uterine fibroids, the first approved medication...

2013-03-27 08:31:25

STUDY WILL EVALUATE SIX MONTHS OF TREATMENT IN 280 SUBJECTS SAN DIEGO, March 27, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that a Phase IIb clinical trial to evaluate elagolix for the treatment of uterine fibroids has been initiated. Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist, in development by AbbVie for the treatment of uterine fibroids and endometriosis. Neurocrine and AbbVie entered into a collaboration and license...

2013-01-09 04:21:17

LIVERMORE, Calif., Jan. 9, 2013 /PRNewswire/ -- Halt Medical, Inc. introduced today a team to drive commercialization of the Acessa System, a newly FDA cleared medical device to treat uterine fibroids. "It gives me great pleasure to introduce Rodney Marcy as our Senior Vice President of Sales and Marketing," said Jeffrey Cohen, Halt's Chief Executive Officer. "Rodney has extensive commercial experience in the medical device field, and women's health sector. This will be instrumental in our...

2013-01-02 04:20:26

LIVERMORE, Calif., Jan. 2, 2013 /PRNewswire/ -- Halt Medical, Inc. announced today that it has received $15 million of financing to support commercialization of the Acessa(TM) System, a newly FDA cleared medical device to treat uterine fibroids. (Logo: http://photos.prnewswire.com/prnh/20130102/LA35495LOGO ) "We are delighted that American Capital, Ltd. has chosen to once again lead financing for this critical new medical device," stated Jeff Cohen, Halt Medical Chief Executive Officer....